FDA Issues Complete Response Letter for Joenja® sNDA in Pediatric APDS
Summary
Pharming Group received a Complete Response Letter from the FDA for its sNDA for Joenja® in children aged 4-11 with APDS, citing issues with pediatric dosing data and an analytical method, delaying market expansion.
Key Events
-
FDA Issues Complete Response Letter
The U.S. FDA issued a CRL for the sNDA of Joenja® (leniolisib) for children aged 4-11 years with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
-
Reasons for Delay
The CRL cited concerns about potential underexposure in lower-weight pediatric patients, requiring additional pharmacokinetic data, and an issue with an analytical method used for production batch testing.
-
Existing Approval Unaffected
The current FDA approval for Joenja® in patients aged 12 years and older for APDS remains unaffected by this regulatory action.
-
Company Response
Pharming Group plans to address the identified issues, work closely with the FDA, and request a Type A meeting to determine next steps for resubmission.
Analysis
The U.S. FDA's Complete Response Letter (CRL) for Joenja®'s supplemental New Drug Application (sNDA) for children aged 4-11 with APDS represents a setback for Pharming Group. While the existing approval for patients 12 and older remains unaffected, this CRL delays market expansion into a younger pediatric population. The FDA cited concerns regarding potential underexposure in lower-weight pediatric patients, requiring additional pharmacokinetic data, and an issue with an analytical method. The company's plan to address these issues and request a Type A meeting indicates a path forward, but it will incur additional time and resources before potential approval for this indication.
At the time of this filing, PHAR was trading at $17.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.50 to $21.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.